GlassScriptPhysician profile
Bernardo J Arias
NPI 1912992132
$18,021.61
in general payments reported to CMS, 2019-2025
34 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $1,441 · 2021: $2,788 · 2022: $2,741 · 2023: $3,274 · 2024: $3,173 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,598 · Education: $53.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,598.32 |
| Education | $53.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,810.28 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,577.87 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,435.65 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,388.47 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,357.93 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $1,273.47 | 2019-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $1,254.23 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $948.54 | 2021-2025 | Azstarys, Adlarity |
| Neurocrine Biosciences, INC. | $898.69 | 2019-2025 | Ingrezza |
| Tris Pharma INC | $760.07 | 2020-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Ironshore Pharmaceuticals INC. | $732.01 | 2019-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $650.60 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $443.20 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $432.58 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $409.06 | 2020-2023 | Belsomra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $338.79 | 2019-2025 | Sublocade |
| Allergan, INC. | $288.85 | 2019-2021 | |
| Almatica Pharma LLC | $285.15 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $275.23 | 2021-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $246.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $223.72 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $187.42 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $170.37 | 2024-2025 | Xelstrym |
| Adlon Therapeutics L.P. | $157.67 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $123.16 | 2023-2024 | Quviviq |
| Neuronetics, INC. | $100.60 | 2019-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $46.96 | 2020-2021 | |
| Shire North American Group INC | $46.70 | 2019 | |
| Braeburn INC. | $44.72 | 2024 | Brixadi |
| Neos Therapeutics, LP | $37.86 | 2019-2024 | Adzenys Xr-Odt |
| Boston Scientific Corporation | $25.88 | 2025 | Ams 700 |
| Livanova USA, INC. | $20.50 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Tempus Ai, INC | $16.38 | 2024 | |
| Alfasigma USA, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernardo Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.